CAS 2135696-72-7

Tarlox-TKI

CAS : 2135696-72-7

Tarlox-TKI

Degré de pureté : ≥95%

Masse moléculaire : 461.74g/mol

Ref: 54-BUP21719

Tarlox-TKI

CAS : 2135696-72-7

Tarlox-TKI is a drug with potential anti-cancer activity, which acts as a selective inhibitor of the enzyme P2Y receptor. It binds to the α7 nicotinic acetylcholine receptor, preventing neuronal death and skin cancer. Tarlox-TKI has been shown to inhibit xenograft tumor growth in mice and also suppresses transcriptional regulation of genes involved in autoimmune diseases. Tarlox-TKI interacts with toll-like receptor 4 (TLR4) and inhibits the expression of the gene 2-aminoethoxydiphenyl borate (APBD). Tarlox-TKI prevents p21 from becoming activated by inhibiting polymerase chain reaction (PCR), which leads to inhibition of leukemia inhibitory factor (LIF).

Formule : C₁₉H₁₈BrClN₆O

Degré de pureté : Min. 95%

Masse moléculaire : 461.7 g/mol

Ref: 3D-KKD69672

Tarlox-TKI

CAS : 2135696-72-7

Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.

Formule : C₁₉H₁₈BrClN₆O

Degré de pureté : 97.03%

Couleur et forme : Solid

Masse moléculaire : 461.74

Ref: TM-T11761